Cargando…
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
OBJECTIVE: To assess the relationship between CD56(bright) natural killer (NK) cells and multiple sclerosis (MS) disease activity in patients with relapsing-remitting MS treated with daclizumab high-yield process (DAC HYP). METHODS: Data were from patients enrolled in a 52-week randomized, double-bl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309527/ https://www.ncbi.nlm.nih.gov/pubmed/25635261 http://dx.doi.org/10.1212/NXI.0000000000000065 |
_version_ | 1782354712977211392 |
---|---|
author | Elkins, J. Sheridan, J. Amaravadi, L. Riester, K. Selmaj, K. Bielekova, B. Parr, E. Giovannoni, G. |
author_facet | Elkins, J. Sheridan, J. Amaravadi, L. Riester, K. Selmaj, K. Bielekova, B. Parr, E. Giovannoni, G. |
author_sort | Elkins, J. |
collection | PubMed |
description | OBJECTIVE: To assess the relationship between CD56(bright) natural killer (NK) cells and multiple sclerosis (MS) disease activity in patients with relapsing-remitting MS treated with daclizumab high-yield process (DAC HYP). METHODS: Data were from patients enrolled in a 52-week randomized, double-blind, placebo-controlled study of DAC HYP and its extension study. Assessments included relationships of CD56(bright) NK cell numbers (identified using fluorescence-activated cell sorting) at weeks 4 and 8 with the numbers of new or newly enlarging T2-hyperintense lesions between weeks 24 and 52 and the annualized relapse rate. RESULTS: In DAC HYP–treated patients but not placebo-treated patients, the numbers of CD56(bright) NK cells increased over 52 weeks of treatment, and their numbers at weeks 4 and 8 predicted the number of new or newly enlarging T2-hyperintense lesions between weeks 24 and 52 of treatment (p ≤ 0.005 for each comparison). Similar but nonsignificant trends were observed between CD56(bright) NK cell counts and the annualized relapse rate in DAC HYP–treated patients. DAC HYP–treated patients who showed lower levels of expansion of CD56(bright) NK cells still developed fewer new or newly enlarging T2-hyperintense lesions than placebo-treated patients during the first year of treatment. CONCLUSIONS: CD56(bright) NK cells appear to mediate some of the treatment-related effects of DAC HYP, but their numbers do not account for the full effect of DAC HYP on MS-related outcomes. |
format | Online Article Text |
id | pubmed-4309527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-43095272015-01-29 CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS Elkins, J. Sheridan, J. Amaravadi, L. Riester, K. Selmaj, K. Bielekova, B. Parr, E. Giovannoni, G. Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To assess the relationship between CD56(bright) natural killer (NK) cells and multiple sclerosis (MS) disease activity in patients with relapsing-remitting MS treated with daclizumab high-yield process (DAC HYP). METHODS: Data were from patients enrolled in a 52-week randomized, double-blind, placebo-controlled study of DAC HYP and its extension study. Assessments included relationships of CD56(bright) NK cell numbers (identified using fluorescence-activated cell sorting) at weeks 4 and 8 with the numbers of new or newly enlarging T2-hyperintense lesions between weeks 24 and 52 and the annualized relapse rate. RESULTS: In DAC HYP–treated patients but not placebo-treated patients, the numbers of CD56(bright) NK cells increased over 52 weeks of treatment, and their numbers at weeks 4 and 8 predicted the number of new or newly enlarging T2-hyperintense lesions between weeks 24 and 52 of treatment (p ≤ 0.005 for each comparison). Similar but nonsignificant trends were observed between CD56(bright) NK cell counts and the annualized relapse rate in DAC HYP–treated patients. DAC HYP–treated patients who showed lower levels of expansion of CD56(bright) NK cells still developed fewer new or newly enlarging T2-hyperintense lesions than placebo-treated patients during the first year of treatment. CONCLUSIONS: CD56(bright) NK cells appear to mediate some of the treatment-related effects of DAC HYP, but their numbers do not account for the full effect of DAC HYP on MS-related outcomes. Lippincott Williams & Wilkins 2015-01-22 /pmc/articles/PMC4309527/ /pubmed/25635261 http://dx.doi.org/10.1212/NXI.0000000000000065 Text en © 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Article Elkins, J. Sheridan, J. Amaravadi, L. Riester, K. Selmaj, K. Bielekova, B. Parr, E. Giovannoni, G. CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS |
title | CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS |
title_full | CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS |
title_fullStr | CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS |
title_full_unstemmed | CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS |
title_short | CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS |
title_sort | cd56(bright) natural killer cells and response to daclizumab hyp in relapsing-remitting ms |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309527/ https://www.ncbi.nlm.nih.gov/pubmed/25635261 http://dx.doi.org/10.1212/NXI.0000000000000065 |
work_keys_str_mv | AT elkinsj cd56brightnaturalkillercellsandresponsetodaclizumabhypinrelapsingremittingms AT sheridanj cd56brightnaturalkillercellsandresponsetodaclizumabhypinrelapsingremittingms AT amaravadil cd56brightnaturalkillercellsandresponsetodaclizumabhypinrelapsingremittingms AT riesterk cd56brightnaturalkillercellsandresponsetodaclizumabhypinrelapsingremittingms AT selmajk cd56brightnaturalkillercellsandresponsetodaclizumabhypinrelapsingremittingms AT bielekovab cd56brightnaturalkillercellsandresponsetodaclizumabhypinrelapsingremittingms AT parre cd56brightnaturalkillercellsandresponsetodaclizumabhypinrelapsingremittingms AT giovannonig cd56brightnaturalkillercellsandresponsetodaclizumabhypinrelapsingremittingms |